4,9-二甲基-1,2,3,4-四氢咔唑 | 683800-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4,9-二甲基-1,2,3,4-四氢咔唑
• 英文名称: 4,9-dimethyl-2,3,4,9-tetrahydro-1H-carbazole
• 英文别名: 4,9-dimethyl-1,2,3,4-tetrahydrocarbazole
• CAS: 683800-15-9
• 化学式: C₁₄H₁₇N
• 分子量: 199.296
• InChiKey: TYZOXZPLANVAAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4,9-二甲基-1,2,3,4-四氢咔唑 在 palladium on activated charcoal 作用下， 以88%的产率得到4,9-dimethyl-9H-carbazole
  参考文献：
  名称：

  铂催化吲哚与未活化烯烃的分子内烷基化

  摘要：

  1-甲基-2-（4-戊烯基）吲哚 (1) 与催化量的 PtCl2 (2 mol %) 在含有痕量 HCl (5 mol %) 的二恶烷中在 60 °C 下反应 24 小时，导致4,9-二甲基-2,3,4,9-四氢-1H-咔唑(2)的分离，产率为92%。铂催化的 2-(4-戊烯基) 吲哚环化耐受 4-戊烯基链每个位置的取代。此外, 该协议适用于四氢-β-咔啉酮的合成, 对未受保护的吲哚环化有效。2-（3-丁烯基）吲哚经历了铂催化的环化反应，具有独特的 6-endo-trig 区域选择性。机理研究建立了铂催化 2-烯基吲哚环化的机制，涉及吲哚对铂络合烯烃的亲核攻击。

  DOI：

  10.1021/ja031814t
• 作为产物：
  描述：

  1-methyl-2-(4-pentenyl)indole 在 platinum(II) chloride 作用下， 以92%的产率得到4,9-二甲基-1,2,3,4-四氢咔唑
  参考文献：
  名称：

  烯基吲哚的钯催化环化/碳烷氧基化

  摘要：

  1-甲基-2-（4-戊烯基）吲哚与催化量的 PdCl2(CH3CN)2（5 mol%）和化学计量的 CuCl2（3 当量）在甲醇中在 CO（1 个大气压）下在室温下反应30 分钟导致环化/碳烷氧基化以 83% 的分离产率形成相应的四氢咔唑，作为单一区域异构体。钯催化的 2-(4-戊烯基) 吲哚的环化/碳烷氧基化耐受沿烯基链和内部和顺式末端烯烃位置的取代。钯催化的环化/碳烷氧基化可耐受一系列醇，可有效环化 2-(3-丁烯基)吲哚、3-(3-丁烯基)吲哚、3-(4-戊烯基)吲哚和 2-(5) -己烯基）吲哚。

  DOI：

  10.1021/ja046810i

文献信息

• USE OF SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS TO DECREASE SPLA2 LEVELS
  申请人：Trias Joaquim

  公开号：US20090062369A1

  公开（公告）日：2009-03-05

  Administration of sPLA 2 inhibitors has been found to decrease sPLA 2 levels in human serum. Provided herein are methods of decreasing serum sPLA 2 levels in a subject in need thereof, as well as methods for accurately measuring sPLA 2 levels in a serum sample.
• TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES
  申请人：Trias Joaquim

  公开号：US20090131396A1

  公开（公告）日：2009-05-21

  Administration of sPLA 2 inhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLA 2 inhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLA 2 inhibitors. Significantly, administration of sPLA 2 inhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLA 2 inhibitors and statins resulted in a synergistic decrease in plaque content. Therefore, also provided herein are compositions comprising one or more sPLA 2 inhibitors and one or more compounds used in the treatment of CVD, such as for example statins, and methods of using these compositions to treat dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome.
• TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES
  申请人：Hislop Colin

  公开号：US20100160361A1

  公开（公告）日：2010-06-24

  Administration of sPLA 2 inhibitors in combination with statins has been found to reduce major adverse cardiac events (MACEs), inflammatory biomarker levels, and LDL-C levels in subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were unexpected given previous results showing that statins alone are insufficient to satisfactorily reduce MACEs and inflammation in this high-risk population. Therefore, provided herein are methods of treating MACEs, treating ACS, inhibiting inflammation, and lowering cholesterol levels in a subject who has previously experienced an ACS event by administering one or more sPLA 2 inhibitors alone or in combination with one or more statins.
• SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA
  申请人：HISLOP Colin

  公开号：US20100204249A1

  公开（公告）日：2010-08-12

  Niacin drugs are frequently utilized as a therapeutic to treat CVD, increase HDL levels, and/or decrease TG levels. As disclosed herein, it has been found that administration of one or more sPLA 2 inhibitors in combination with one or more niacin drugs unexpectedly results in a synergistic increase in HDL levels and a synergistic decrease in TG levels. Therefore, compositions, methods, and kits are provided for treating CVD, increasing HDL levels, decreasing TG levels, and improving HDL/LDL ratios.
• US8048880B2
  申请人：——

  公开号：US8048880B2

  公开（公告）日：2011-11-01